Mitsubishi Tanabe to pay $1.1bn for Parkinson's drug formulator Neuroderm
![iStock/sudok1](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_large/2/2/3/7/5987322-1-eng-GB/Mitsubishi-Tanabe-to-pay-1.1bn-for-PD-drug-formulator-Neuroderm.jpg)
Neuroderm’s lead product candidate – ND0612 – is a liquid formulation combining levodopa and carbidopa. The production – which is in Phase III trials in the US - is designed for continuous administration using specially developed, belt worn pump.
The Israel-based firm has a second Parkinson’s disease drug ND0701 (apomorphine) in development, as well as a transdermal CNS disease medication called ND0801 (nicotide and opipramol).